Health Economics›Multiple myeloma›Maintenance after first-line therapy

Maintenance after first-line therapy

Multiple myeloma · 29 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 12 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carfilzomib monotherapy Variant #01	—	R 175 814	28d	—	~10.2 mo	~11	~R 941 453 PFS proxy · indirect	1
KRd Variant #08	—	R 147 838	28d	59.1 mo	—	18	R 1 515 571 PFS proxy	1
Daratumumab monotherapy Variant #01	—	R 84 235	28d	—	—	13	R 1 095 049 PFS proxy	1
Carfilzomib and Lenalidomide (KR) Variant #01	—	R 68 344	28d	—	—	27	R 1 779 132 PFS proxy	1
Thalidomide and Dexamethasone (TD) Variant #06	—	R 64 543	30d	36.0 mo	—	18	R 678 160 PFS proxy	—
Ixazomib monotherapy Variant #01	—	R 39 177	28d	22.0 mo	—	12	R 470 130 PFS proxy	2
RVD Variant #07	—	R 17 832	21d	~43.0 mo	—	~39	~R 415 913 PFS proxy · indirect	9
Thalidomide and Prednisone (TP) Variant #01	—	R 16 710	28d	—	—	52	R 868 923 PFS proxy	1
Thalidomide and Prednisolone (TP) Variant #01	—	R 8 378	28d	—	—	14	R 108 950 PFS proxy	1
Thalidomide monotherapy Variant #04	—	R 8 341	28d	23.0 mo	—	39	R 325 306 PFS proxy	1
Bortezomib and Dexamethasone (Vd) Variant #01	—	R 7 456	28d	~9.4 mo	~38.7 mo	~8	~R 59 651 PFS proxy · indirect	10
Bortezomib and Prednisone (VP) Variant #01	—	R 6 851	90d	—	—	~12	~R 82 212 indirect	—
Bortezomib monotherapy Variant #03	—	R 6 762	21d	~30.3 mo	—	~8	~R 54 096 PFS proxy · indirect	5
Lenalidomide and Dexamethasone (Rd) Variant #02	—	R 4 309	28d	~21.0 mo	~55.4 mo	~40	~R 132 764 PFS proxy · indirect	26
VT Variant #01	—	R 3 776	14d	—	—	~2	~R 7 552 indirect	—
Isa-Rd Variant #01 Partial	—	R 2 525	28d	—	—	~19	~R 47 979 indirect	—
Lenalidomide and Prednisone (RP) Variant #02	—	R 2 182	28d	37.5 mo	—	5	R 10 910 PFS proxy	1
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	41.0 mo	113.8 mo	13	R 28 314 PFS proxy	4
Interferon alfa-2b and Thalidomide Variant #01 Partial	—	R 2 085	7d	27.7 mo	—	2	R 4 171 PFS proxy	1
Dexamethasone monotherapy Variant #03	—	R 1 215	28d	—	—	~4	~R 4 861 indirect	—
Interferon alfa and Dexamethasone Variant #01 Partial	—	R 347	28d	—	—	~2	~R 694 indirect	—
Prednisone monotherapy Variant #11 Partial	—	R 138	7d	~2.2 mo	~14.1 mo	~1	~R 138 PFS proxy · indirect	8
Interferon alfa-2b and Prednisone Variant #01 Partial	—	R 6	7d	—	—	~2	~R 12 indirect	—
Prednisolone monotherapy Variant #03	—	R 4	84d	—	—	1	R 4 PFS proxy	1
Placebo Partial	—	—	—	22.2 mo	—	—	—	2
Interferon alfa monotherapy Variant #01 Partial	—	—	7d	—	—	~2	—	—
Observation Partial	—	—	—	—	—	—	—	1
Interferon alfa-2b monotherapy Variant #01 Partial	—	—	28d	13.2 mo	—	6	—	1
Interferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	~5.4 mo	~17.5 mo	~11	—	10

29 of 29 regimens shown